Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 3022 2023-11-28 05:55:34 |
2 references update Meta information modification 3022 2023-11-30 03:48:40 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Akhiiarova, K.; Khusainova, R.; Minniakhmetov, I.; Mokrysheva, N.; Tyurin, A. Factors Affecting Peak Bone Mass. Encyclopedia. Available online: (accessed on 18 June 2024).
Akhiiarova K, Khusainova R, Minniakhmetov I, Mokrysheva N, Tyurin A. Factors Affecting Peak Bone Mass. Encyclopedia. Available at: Accessed June 18, 2024.
Akhiiarova, Karina, Rita Khusainova, Ildar Minniakhmetov, Natalia Mokrysheva, Anton Tyurin. "Factors Affecting Peak Bone Mass" Encyclopedia, (accessed June 18, 2024).
Akhiiarova, K., Khusainova, R., Minniakhmetov, I., Mokrysheva, N., & Tyurin, A. (2023, November 28). Factors Affecting Peak Bone Mass. In Encyclopedia.
Akhiiarova, Karina, et al. "Factors Affecting Peak Bone Mass." Encyclopedia. Web. 28 November, 2023.
Factors Affecting Peak Bone Mass

Peak bone mass is the amount of bone tissue that is formed when a stable skeletal state is achieved at a young age. To date, there are no established peak bone mass standards nor clear data on the age at which peak bone mass occurs. At the same time, the level of peak bone mass at a young age is an important predictor of the onset of primary osteoporosis. 

peak bone mass PBM aBMD bone mineral density

1. Hormonal Background

One of the key roles in the regulation of bone metabolism is played by sex hormones. Thus, estrogens limit the production of osteoclastogenic cytokines produced by osteoblast cells and thus inhibit osteoclast formation and bone resorption [1]. Changes in the hormonal background in different age periods have a significant effect on bone metabolism. The effect of hormonal background was studied in mice in the most detail. For example, deletion of the androgen receptor (AR) in male mice causes high bone turnover, increased bone resorption, and reduced cortical and cancellous bone mass. Targeted deletion of AR in mature osteoblasts, however, reduces the mass of the bone spongy substance, but does not affect the cortical layer of bone [2]. Over the past 10 years, extensive data have indicated the involvement of oxidative stress in increased bone resorption associated with estrogen or androgen deficiency [3]. RANKL and MCS-F (macrophage colony-stimulating factor) are two cytokines that are necessary for the formation of osteoclasts [4]; they stimulate the intracellular accumulation of H2O2, which is necessary for osteoclast adaptation, differentiation, and survival [5]. This hypothesis has been proven empirically: in mice capable of synthesizing human catalase, an enzyme that utilizes H2O2 in mitochondria, there was an increase in cortical and spongy bone mass due to a decrease in the number of osteoclasts [2]. In adulthood, certain endocrine pathologies associated with estrogen, such as complete androgen insensitivity syndrome due to complete androgen resistance, premature ovarian failure, or Turner syndrome, can lead to a decrease in aBMD in women at the level of the lumbar spine and femoral neck [6].
On the other hand, it is interesting that gender-supportive hormone therapy in trans women (with estradiol and antiandrogens) and in trans men (with testosterone) resulted in an increase in bone metabolism in young trans men, while it decreased in trans women, demonstrating the crucial role of estrogen in the regulation of bone resorption [7].

2. Microbiome

Intestinal microbiota makes a certain contribution to the metabolism of connective tissue and bone tissue. Yan et al. (2017) reported that short-chain fatty acids (SCFAs) produced by the microbiota induced insulin-like growth factor 1 (IGF-1), which promotes bone growth [8]. Treatment of mice with microbiota metabolism products, including SCFAs, propionate, and butyrate, significantly increases bone mass and prevents postmenopausal and inflammation-induced bone loss, and propionate and butyrate induce metabolic reprogramming of osteoclasts, which leads to suppression of bone resorption activity by osteoclasts [9][10][11]. The consumption of indigestible food components is one of the ways in which it is possible to change the gut microbiota to improve the health of the host. Dietary components, such as prebiotic dietary fiber, are associated with positive shifts in the composition of the intestinal microbial community [12]. A study conducted among adolescents showed that the consumption of various prebiotics, such as galactooligosaccharides and soluble corn fiber, which can be fermented to SCFAs, led to increased absorption of calcium in the intestine and was associated with the relative content of Parabacteroides, Bifidobacterium, Bacteroides, Butyricicoccus, Oscillibacter, and Dialister species measured in feces, and the change in the intestinal microbiome towards enrichment with bacteria of the genera Dialister and Faecalibacterium, on the contrary, was associated with the presence of osteoporosis [13]. In addition, in clinical trials, it was reported that the consumption of SCFAs in women could improve bone metabolism with increased activity of bone-specific alkaline phosphatase [14]. Supplements with Bacillus subtilis, Lactobacilli, and multi-species probiotics have demonstrated a beneficial effect not only on the human gut microbiota [15], but also on markers of bone metabolism [16]. Strain-specific probiotics can reduce oxidative stress by producing several antioxidant molecules, e.g., glutathione, folic acid, and exopolysaccharide. In addition, short-chain fatty acids produced by some gut microbiota may also help reduce oxidative stress by promoting the production of antioxidant molecules [17].

3. Quality Body Composition

The understanding of the effect of adipose tissue on bone metabolism is still ambiguous, and often the results of studies contradict each other. It is worth considering the adipose tissue of the bone marrow and adipose tissue in general. Mesenchymal stromal cells (MSCs) are multipotent progenitors capable of differentiation into osteoblasts and can potentially serve as a source of cell therapy for bone regeneration. Many factors have been shown to regulate the differentiation of MSCs into the osteogenic lineage, such as the cyclooxygenase-2 (COX2)/prostaglandin E2 (PGE2) signaling pathway, which is critical for bone repair. PGE2 binds four different EP1-4 receptors (prostaglandin receptors) [18]. Thus, adipocytes themselves stimulate the differentiation of MSCs into adipocytes, and not into osteoblasts. In addition, adipocytes in the bone marrow microenvironment release a range of pro-inflammatory and immunomodulatory molecules that enhance osteoclast formation and activation, thereby contributing to bone fragility. In vivo analysis of the relative content of saturated and unsaturated fatty acids in the bone marrow indicates a locally dependent marrow fat composition and an association between an elevated unsaturation index and bone health. Most diseases with bone loss, in which an altered composition of the bone marrow develops, have aging and/or chronic inflammation as common factors. Both saturated and unsaturated fatty acids form lipid forms that are active mediators of the inflammatory process [19]. However, the intervention of alpha-lipoic acid (ALA) inhibited the RANKL-induced proliferation and differentiation of osteoclasts. ALA also inhibited bone resorption activity, suppressed RANKL-induced transcription factors c-Fos, c-Jun, and NFATC1 (nuclear factor of activated T cells) in combination with markers of osteoclasts such as TRAP (prediction of affinity for transcription factor), OSCAR (receptor associated with osteoclasts), cathepsin K, and β3-integrin [20]. On the other hand, excessive accumulation of adipose tissue performs the role of a mechanical vertical load contributing to the build-up of bone tissue. In this case, bone quality and structure are the result of a balance of inflammatory and mechanical incentive stimuli [21].
Data on the influence of sex on body mass index (BMI) and aBMD are also contradictory. There is a point of view that aBMD values increase with an increase in BMI only in men [22]. Nevertheless, a number of authors have noted that increasing BMI to the values of the “metabolic syndrome” leads to decreasing aBMD for both men and women [23]. In another study among young Hispanic and non-Hispanic girls, Megan Hetherington-Rauth et al. found a positive contribution of fat mass to bone strength in vBMD; however, negative associations were also found with the content and thickness of the cortical bone of the radius [24]. Also, Zeyu Xiao et al. in a sample of young Chinese adults found that both total lean body mass and fat mass were significantly positively associated with aBMD in both genders [25]. Nielsen et al. obtained results that individuals aged 15–19 years who lost weight during follow-up showed slower progression of aBMD gain compared to those who gained weight, but weight loss or BMI reduction over 2 years was not associated with a net loss of aBMD [26].
In a study on FAT-ATTAC transgenic mice, Lagerquist et al. induced adipocyte apoptosis and assessed bone metabolism by X-ray absorptiometry and found no effect of adipose tissue reduction on bone resorption [27].
Bones and muscles are two deeply interconnected organs with integrated growth and locomotion [28]. In a study involving 416 women and 334 men aged 20 to 30 years in Vietnam, the association of body composition and aBMD at the lumbar spine and femoral neck was assessed using dual-energy X-ray absorptiometry. Peak aBMD in men was higher than in women, and the difference was more pronounced in the femoral neck region than in the lumbar spine, and fat-free mass was the only predictor of aBMD for both men and women. Each kilogram of increase in muscle mass was associated with an increase in BMD by about 0.01 g/cm2 [29]. Winther et al. also found that higher levels of aBMD corresponded to higher levels of fat-free mass in both genders, but higher aBMD at higher levels of fat mass was found only in girls [30].
Muscle paralysis also contributes to bone mineral density. Paralysis caused by botulinum toxin causes bone loss in adult mice and slows down the healing of fractures [31].
Bones and muscles act as secretory endocrine organs that affect each other’s function. Biochemical crosstalk occurs through myokines such as myostatin, irisin, interleukin IL-6, IL-7, IL-15, insulin-like growth factor-1, fibroblast growth factor, and β-aminoisobutyric acid, as well as through factors of bone origin, including FGF23, prostaglandin E2, transforming factor growth of β, osteocalcin, and sclerostin [32]. Myostatin is member of the transforming growth factors-beta (TGF-beta) superfamily, which is highly expressed in skeletal muscles. Loss of myostatin function in mice led to an increase in muscle mass, increased bone formation, and an increase in bone cross-section in most anatomical areas, including limbs, spine, and jaw in mice [33]. Myostatin inhibitors such as ACVR2B/Fc, a soluble myostatin decoy receptor, have been shown to prevent loss of both muscle and bone tissue in models of muscular dystrophy [34]. In vitro studies on mice have also shown that myostatin enhances RANKL-induced osteoclastogenesis [35]. Myostatin is also expressed in the early stages of fracture healing, and myostatin deficiency leads to an increase in the size and strength of the callus during fracture. Taken together, these data suggest that myostatin may affect the proliferation and differentiation of osteogenesis progenitor cells and that myostatin antagonists and inhibitors may be therapeutically useful for increasing both muscle mass and bone. Myostatin directly affects osteocyte function by suppressing exosomal miR-218 microRNA and thus inhibits osteoblast differentiation [36].

4. Smoking

The negative impact of smoking on various systems and organs is multifaceted. Mattias Callréus et al. investigated the effects of smoking among women aged 25 years, but statistically significant differences were found only in the levels of aBMD of the femoral neck. Similarly, lower aBMD, in comparison with the control, persisted for up to 24 months after quitting smoking, becoming comparable to those who had never smoked after 24 months [37]. To further evaluate these outcomes, a meta-analysis of 14 prospective studies, information was conducted, which showed that, compared with those who have never smoked, cigarette smoking increased the risk of hip fracture in men, especially in current smokers [38]. Another study has also found an association between smoking and an increased risk of fractures [39]. Both active and passive smoking negatively affect bone mass; quitting smoking seems to reverse the effect of smoking and improve bone health [40]. In men, regardless of age, method, and site of bone density measurement, cross-sectional studies showed that smokers had significantly lower aBMD than non-smokers [41]. In bone studies, smoking was associated with lower aBMD, increased risk of fractures, periodontitis, loss of alveolar bone, and rejection of dental implants [42]. In a large NHANES III study involving 14,500 subjects, the bone mineral density of the femoral neck in smokers was numerically lower than in never-smokers, but the statistical significance of the difference was not reached [43][44]. The data on cannabis smoking are contradictory. Thus, bone mineral density (Z-criterion) was significantly lower in avid cannabis users compared to the control group in the lumbar spine, hip neck, and hip as a whole [45]; however, it was found that the cannabinoid receptors CB1 and CB2 were expressed in bones and regulate bone homeostasis in rodents and humans. Cannabis treatment has been shown to improve fracture healing in rats [46].

5. Nutritional Deficiencies (Calcium, Vitamin D, Phosphorus), Lipids, and Food Character

The contribution of calcium and vitamin D to the quality of bone tissue is beyond doubt; the use of sufficient amounts of calcium and vitamin D in childhood and adolescence is of the greatest importance. Vitamin D synthesized in the skin or absorbed with food undergoes a multi-step enzymatic transformation into its active form, 1,25-dihydroxyvitamin D, [1,25(OH) 2 D], followed by interaction with the vitamin D receptor (VDR) to modulate the expression of the target gene [47]. Vitamin D can support skeletal health and improve bone mineralization by increasing calcium absorption in the intestine, reducing secondary hyperparathyroidism, and reducing bone resorption [48]; moreover, increased calcium intake in combination with vitamin D reduces the rate of loss of minerals in the bones without harm to the intestinal microbiota. Guo-Hau Gou et al. described the positive effect of daily intake of vitamin D and magnesium on hip neck aBMD in female participants aged 8–11 years [49]. Zhou also proved that higher intake of calcium and vitamin D was associated with higher total hip and hip neck aBMD in young men (16–18 years old), and cumulatively high levels of calcium and vitamin D intake over time contributed to better maintenance of aBMD in the lumbar spine and femurs in adult women [50]. Neville et al. also described the positive effect of vitamin D on hip neck aBMD in adolescent girls, but not in the lumbar spine [51]. Krstic et al. described the positive effect of vitamin D intake and physical activity on young mice, explaining the mechanism by hypomethylation of the RXRA (Retinoid X Receptor Alpha) gene DNA, which together with the vitamin D receptor forms a mechanism that transmits the nuclear effects of vitamin D [52].
The question of the effect of dietary lipids on bone tissue remains open. In a mouse study, a high-lipid diet (HLD) resulted in osteoclast activation, a decrease in trabecular bone volume, along with an increase in bone marrow deposition compared to a low-fat diet group [53]. In addition, HLD led to an increase in bone marrow adipose tissue and changes in the bone marrow microenvironment along with a pro-inflammatory environment, which could contribute to a negative effect on bone metabolism. At present, the effect of adipose tissue on bone metabolism is not fully understood [54].

6. Physical Activity, Lifestyle, Psychoemotional Status

There is a positive relationship between the incidence of fractures and the level of physical activity due to the increased risk of falls during physical activity. Thus, although physical activity is critical for bone modeling, children with higher levels of physical activity are more likely to have fractures [55]. Weekly physical activity has a positive effect on BMC and bone mineral density in both boys and girls during puberty when exercising 1–2 times a week [56]. Physical exercises at school in terms of time are effective for increasing aBMD and/or vBMD in children and adolescents, but should include high-intensity exercises, such as high-impact jumps [57]. Physical activity 3 times a week for 40 min in ball games or circular strength training throughout the school year improves bone mineralization and some aspects of muscle fitness of children aged 8–10 years, suggesting that well-organized intensive physical education classes can positively affect the development of the musculoskeletal system and health in children early age [58].
Sleep also affects bone mineralization. An unbalanced sleep pattern contributes to bone loss and an increased risk of osteoporosis. Thus, healthy sleep contributes to the prevention of osteoporosis [59].
Psychoemotional status, as well as associated pathological conditions, also affect bone health. So, depression was associated with lower aBMD, especially in the spine, in white men, and non-highly educated populations. Moreover, people with depression were more likely to suffer fractures and osteoporosis [60].

7. Early Antropometric Characteristics

Body length at birth and height under the age of 7 years were positively associated with mineral density of the femoral neck, and growth in all studied age periods was positively associated with the area of the spine. Growth under the age of 7 years was associated with the mineral density of the femoral neck [61]. Bone mineral density may also be affected by birth weight, among other things. In a meta-analysis by Baird et al. (14 studies involving men and women aged 18–80 years), a positive relationship was found between birth weight and aBMD of the lumbar spine in adulthood, and this relationship was stronger for women [62]. This hypothesis was also confirmed in the PEAK-25 study conducted in Sweden (1061 women aged 25 years) [63].

8. Heredity and Genetics

Data regarding the association of PBM with genes and polymorphic variants in humans are incomplete [64][65]. Wei-jia Yu and colleagues (2020) reported associations between polymorphic variants of the gene LGR4 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 4) and bone metabolism. Their study involved 1296 participants from nuclear families (mother, father, son) and they found an association of polymorphic variants rs11029986 and total hip aBMD and rs12796247, rs2219783 with lumbar spine aBMD [66]. Another study by Zheng et al. (2016) described associations of six SNPs (rs6126098, rs6091103, rs238303, rs6067647, rs8126174, and rs4811144) in the CTNNBL1 gene (Beta-catenin-like protein 1) and peak bone mineral density of the lumbar spine, femoral neck, or the entire femur [67]. Zhao et al. (2017) conducted a study on 1296 Chinese men and found positive associations between rs9585961 METTL21C (Methyltransferase Like Protein 21C) and aBMD of the lumbar spine and femoral neck, as well as rs9518810 and aBMD of the femoral neck [68]. In a separate study, He et al. (2011) analyzed 401 Chinese nuclear families and described an intrafamily negative relationship between allele C rs16878759 and PBM of the lumbar spine. They also found that the CCC haplotype (containing rs12699800, rs16878759, and rs17619769) had a significant intrafamily association with PBM of the lumbar spine [69]. Chesi et al. (2019) conducted a study using a donor culture of primary MSC. ING3 (Inhibitor of Growth Family Member 3) and EPDR1 (Ependymin Related 1) knockdowns disrupted osteoblast differentiation and increased MSC adipogenic differentiation. ING3 knockdown increased adipogenesis by 8 times, and EPDR1 knockdown by 3.5 times [70]. Furthermore, this group of authors, in a repeated experiment with editing the EPDR1 gene by CRISPR-Cas 9 on an immortalized MSC hFOB1.19 cell culture, confirmed the important role of EPDR1 in osteoblast differentiation [71].
The search for genes involved in bone metabolism continues in mouse models. In modified mice with Wnt16−/− knockout, the thickness of the cortical layer of bone and bone strength were reduced [72]. An intronic variant rs2566752 was associated with aBMD of the spine. A less common allele C from this locus was associated with increased spinal aBMD. This allele was also found to be associated with a reduced risk of fracture in the TwinsUK cohort [73]. Fibroblast growth factor receptor 1 (FGFR1) is an important molecule for skeletal development and bone remodeling. Mice lacking FGFR1 in osteocytes showed an increase in trabecular bone mass at 2 and 6 months of age as a result of increased bone formation and reduced resorption [74].


  1. Almeida, M.; Laurent, M.R.; Dubois, V.; Claessens, F.; O’Brien, C.A.; Bouillon, R.; Vanderschueren, D.; Manolagas, S.C. Estrogens and Androgens in Skeletal Physiology and Pathophysiology. Physiol. Rev. 2017, 97, 135–187.
  2. Carson, J.A.; Manolagas, S.C. Effects of Sex Steroids on Bones and Muscles: Similarities, Parallels, and Putative Interactions in Health and Disease. Bone 2015, 80, 67–78.
  3. Manolagas, S.C. From Estrogen-Centric to Aging and Oxidative Stress: A Revised Perspective of the Pathogenesis of Osteo-porosis. Endocr. Rev. 2010, 31, 266–300.
  4. Park-Min, K.-H. Mechanisms Involved in Normal and Pathological Osteoclastogenesis. Cell. Mol. Life Sci. 2018, 75, 2519–2528.
  5. Yasuda, H. Discovery of the RANKL/RANK/OPG System. J. Bone Miner. Metab. 2021, 39, 2–11.
  6. Szeliga, A.; Maciejewska-Jeske, M.; Męczekalski, B. Bone Health and Evaluation of Bone Mineral Density in Patients with Premature Ovarian Insufficiency. Menopausal Rev. 2018, 17, 112–116.
  7. Vlot, M.C.; Wiepjes, C.M.; de Jongh, R.T.; T’Sjoen, G.; Heijboer, A.C.; den Heijer, M. Gender-Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen. J. Bone Miner. Res. 2019, 34, 1862–1872.
  8. Yan, J.; Charles, J.F. Gut Microbiome and Bone: To Build, Destroy, or Both? Curr. Osteoporos. Rep. 2017, 15, 376–384.
  9. Lucas, S.; Omata, Y.; Hofmann, J.; Böttcher, M.; Iljazovic, A.; Sarter, K.; Albrecht, O.; Schulz, O.; Krishnacoumar, B.; Krönke, G.; et al. Short-Chain Fatty Acids Regulate Systemic Bone Mass and Protect from Pathological Bone Loss. Nat. Commun. 2018, 9, 55.
  10. Li, J.-Y.; Yu, M.; Pal, S.; Tyagi, A.M.; Dar, H.; Adams, J.; Neale Weitzmann, M.; Jones, R.M.; Pacifici, R. Parathyroid Hormone–Dependent Bone Formation Requires Butyrate Production by Intestinal Microbiota. J. Clin. Investig. 2020, 130, 1767–1781.
  11. Jansson, P.-A.; Curiac, D.; Lazou Ahrén, I.; Hansson, F.; Martinsson Niskanen, T.; Sjögren, K.; Ohlsson, C. Probiotic Treatment Using a Mix of Three Lactobacillus Strains for Lumbar Spine Bone Loss in Postmenopausal Women: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial. Lancet Rheumatol. 2019, 1, e154–e162.
  12. Whisner, C.M.; Castillo, L.F. Prebiotics, Bone and Mineral Metabolism. Calcif. Tissue Int. 2018, 102, 443–479.
  13. Xu, Z.; Xie, Z.; Sun, J.; Huang, S.; Chen, Y.; Li, C.; Sun, X.; Xia, B.; Tian, L.; Guo, C.; et al. Gut Microbiome Reveals Specific Dysbiosis in Primary Osteoporosis. Front. Cell. Infect. Microbiol. 2020, 10, 160.
  14. Behera, J.; Ison, J.; Tyagi, S.C.; Tyagi, N. The Role of Gut Microbiota in Bone Homeostasis. Bone 2020, 135, 115317.
  15. Nilsson, A.G.; Sundh, D.; Bäckhed, F.; Lorentzon, M. Lactobacillus reuteri Reduces Bone Loss in Older Women with Low Bone Mineral Density: A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial. J. Intern. Med. 2018, 284, 307–317.
  16. Jafarnejad, S.; Djafarian, K.; Fazeli, M.R.; Yekaninejad, M.S.; Rostamian, A.; Keshavarz, S.A. Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-Blind, Controlled Trial. J. Am. Coll. Nutr. 2017, 36, 497–506.
  17. Wang, Y.; Wu, Y.; Wang, Y.; Xu, H.; Mei, X.; Yu, D.; Wang, Y.; Li, W. Antioxidant Properties of Probiotic Bacteria. Nutrients 2017, 9, 521.
  18. Feigenson, M.; Eliseev, R.A.; Jonason, J.H.; Mills, B.N.; O’Keefe, R.J. PGE2 Receptor Subtype 1 (EP1) Regulates Mesenchymal Stromal Cell Osteogenic Differentiation by Modulating Cellular Energy Metabolism. J. Cell. Biochem. 2017, 118, 4383–4393.
  19. Pino, A.M.; Rodríguez, J.P. Is Fatty Acid Composition of Human Bone Marrow Significant to Bone Health? Bone 2019, 118, 53–61.
  20. Song, J.; Jing, Z.; Hu, W.; Yu, J.; Cui, X. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways. Med. Sci. Monit. 2017, 23, 5056–5069.
  21. Fintini, D.; Cianfarani, S.; Cofini, M.; Andreoletti, A.; Ubertini, G.M.; Cappa, M.; Manco, M. The Bones of Children with Obesity. Front. Endocrinol. 2020, 11, 200.
  22. Loke, S.-S.; Chang, H.-W.; Li, W.-C. Association between Metabolic Syndrome and Bone Mineral Density in a Taiwanese Elderly Population. J. Bone Miner. Metab. 2018, 36, 200–208.
  23. Palermo, A.; Tuccinardi, D.; De Feudis, G.; Watanabe, M.; D’Onofrio, L.; Lauria Pantano, A.; Napoli, N.; Pozzilli, P.; Manfrini, S. BMI and BMD: The Potential Interplay between Obesity and Bone Fragility. Int. J. Environ. Res. Public Health 2016, 13, 544.
  24. Hetherington-Rauth, M.; Bea, J.W.; Blew, R.M.; Funk, J.L.; Hingle, M.D.; Lee, V.R.; Roe, D.J.; Wheeler, M.D.; Lohman, T.G.; Going, S.B. Relative Contributions of Lean and Fat Mass to Bone Strength in Young Hispanic and Non-Hispanic Girls. Bone 2018, 113, 144–150.
  25. Xiao, Z.; Xu, H. Gender-Specific Body Composition Relationships between Adipose Tissue Distribution and Peak Bone Mineral Density in Young Chinese Adults. BioMed Res. Int. 2020, 2020, 6724749.
  26. Nilsen, O.A.; Ahmed, L.A.; Winther, A.; Christoffersen, T.; Thrane, G.; Evensen, E.; Furberg, A.S.; Grimnes, G.; Dennison, E.; Emaus, N. Body Weight and Body Mass Index Influence Bone Mineral Density in Late Adolescence in a Two-Year Follow-Up Study. The Tromsø Study: Fit Futures. JBMR Plus 2019, 3, e10195.
  27. Lagerquist, M.K.; Gustafsson, K.L.; Henning, P.; Farman, H.; Wu, J.; Sjögren, K.; Koskela, A.; Tuukkanen, J.; Ohlsson, C.; Wernstedt Asterholm, I.; et al. Acute Fat Loss Does not Affect Bone Mass. Sci. Rep. 2021, 11, 14177.
  28. Laurent, M.R.; Dubois, V.; Claessens, F.; Verschueren, S.M.P.; Vanderschueren, D.; Gielen, E.; Jardí, F. Muscle-Bone Interactions: From Experimental Models to the Clinic? A Critical Update. Mol. Cell. Endocrinol. 2016, 432, 14–36.
  29. Nguyen, H.G.; Pham, M.T.D.; Ho-Pham, L.T.; Nguyen, T.V. Lean Mass and Peak Bone Mineral Density. Osteoporos. Sarcopenia 2020, 6, 212–216.
  30. Winther, A.; Jørgensen, L.; Ahmed, L.A.; Christoffersen, T.; Furberg, A.S.; Grimnes, G.; Jorde, R.; Nilsen, O.A.; Dennison, E.; Emaus, N. Bone Mineral Density at the Hip and its Relation to Fat Mass and Lean Mass in Adolescents: The Tromsø Study, Fit Futures. BMC Musculoskelet. Disord. 2018, 19, 21.
  31. Hao, Y.; Ma, Y.; Wang, X.; Jin, F.; Ge, S. Short-Term Muscle Atrophy Caused by Botulinum Toxin-A Local Injection Impairs Fracture Healing in the Rat Femur. J. Orthop. Res. 2012, 30, 574–580.
  32. Li, G.; Zhang, L.; Wang, D.; AI Qudsy, L.; Jiang, J.X.; Xu, H.; Shang, P. Muscle-Bone Crosstalk and Potential Therapies for Sarco-Osteoporosis. J. Cell. Biochem. 2019, 120, 14262–14273.
  33. Bonewald, L. Use it or Lose it to Age: A Review of Bone and Muscle Communication. Bone 2019, 120, 212–218.
  34. Puolakkainen, T.; Ma, H.; Kainulainen, H.; Pasternack, A.; Rantalainen, T.; Ritvos, O.; Heikinheimo, K.; Hulmi, J.J.; Kiviranta, R. Treatment with Soluble Activin Type IIB-Receptor Improves Bone Mass and Strength in a Mouse Model of Duchenne Muscular Dystrophy. BMC Musculoskelet. Disord. 2017, 18, 20.
  35. Chen, Y.S.; Guo, Q.; Guo, L.J.; Liu, T.; Wu, X.P.; Lin, Z.Y.; He, H.B.; Jiang, T.J. GDF8 Inhibits Bone Formation and Promotes Bone Resorption in Mice. Clin. Exp. Pharmacol. Physiol. 2017, 44, 500–508.
  36. Qin, Y.; Peng, Y.; Zhao, W.; Pan, J.; Ksiezak-Reding, H.; Cardozo, C.; Wu, Y.; Pajevic, P.D.; Bonewald, L.F.; Bauman, W.A.; et al. Myostatin Inhibits Osteoblastic Differentiation by Suppressing Osteocyte-Derived Exosomal microRNA-218: A Novel Mechanism in Muscle-Bone Communication. J. Biol. Chem. 2017, 292, 11021–11033.
  37. Callréus, M.; McGuigan, F.; Åkesson, K. Adverse Effects of Smoking on Peak Bone Mass May Be Attenuated by Higher Body Mass Index in Young Female Smokers. Calcif. Tissue Int. 2013, 93, 517–525.
  38. Wu, Z.J.; Zhao, P.; Liu, B.; Yuan, Z.C. Effect of Cigarette Smoking on Risk of Hip Fracture in Men: A Meta-Analysis of 14 Prospective Cohort Studies. PLoS ONE 2016, 11, e0168990.
  39. Yuan, S.; Michaëlsson, K.; Wan, Z.; Larsson, S.C. Associations of Smoking and Alcohol and Coffee Intake with Fracture and Bone Mineral Density: A Mendelian Randomization Study. Calcif. Tissue Int. 2019, 105, 582–588.
  40. Al-Bashaireh, A.M.; Haddad, L.G.; Weaver, M.; Chengguo, X.; Kelly, D.L.; Yoon, S. The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms. J. Osteoporos. 2018, 2018, 1206235.
  41. Pompe, E.; Bartstra, J.; Verhaar, H.J.; de Koning, H.J.; van der Aalst, C.M.; Oudkerk, M.; Vliegenthart, R.; Lammers, J.-W.; de Jong, P.; Hoesein, F.M. Bone Density Loss on Computed Tomography at 3-Year Follow-up in Current Compared to Former Male Smokers. Eur. J. Radiol. 2017, 89, 177–181.
  42. Al-Bashaireh, A.M.; Haddad, L.G.; Weaver, M.; Kelly, D.L.; Chengguo, X.; Yoon, S. The Effect of Tobacco Smoking on Mus-Culoskeletal Health: A Systematic Review. J. Environ. Public Health 2018, 2018, 4184190.
  43. Strozyk, D.; Gress, T.M.; Breitling, L.P. Smoking and Bone Mineral Density: Comprehensive Analyses of the Third NATIONAL Health and Nutrition Examination Survey (NHANES III). Arch. Osteoporos. 2018, 13, 16.
  44. Yang, C.Y.; Lai, J.C.Y.; Huang, W.L.; Hsu, C.L.; Chen, S.J. Effects of Sex, Tobacco Smoking, and Alcohol Consumption Osteoporosis Development: Evidence from Taiwan Biobank Participants. Tob. Induc. Dis. 2021, 19, 8210532.
  45. Sophocleous, A.; Robertson, R.; Ferreira, N.B.; McKenzie, J.; Fraser, W.D.; Ralston, S.H. Heavy Cannabis Use Is Associated with Low Bone Mineral Density and an Increased Risk of Fractures. Am. J. Med. 2017, 130, 214–221.
  46. Raphael-Mizrahi, B.; Gabet, Y. The Cannabinoids Effect on Bone Formation and Bone Healing. Curr. Osteoporos. Rep. 2020, 18, 433–438.
  47. Goltzman, D. Functions of Vitamin D in Bone. Histochem. Cell Biol. 2018, 149, 305–312.
  48. LeBoff, M.S.; Chou, S.H.; Ratliff, K.A.; Cook, N.R.; Khurana, B.; Kim, E.; Cawthon, P.M.; Bauer, D.C.; Black, D.; Gallagher, J.C.; et al. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. N. Engl. J. Med. 2022, 387, 299–309.
  49. Gou, G.H.; Tseng, F.J.; Wang, S.H.; Chen, P.J.; Shyu, J.F.; Pan, R.Y. Nutritional Factors Associated with Femoral Neck Bone Mineral Density in Children and Adolescents. BMC Musculoskelet. Disord. 2019, 20, 520.
  50. Zhou, W.; Langsetmo, L.; Berger, C.; Poliquin, S.; Kreiger, N.; Barr, S.I.; Kaiser, S.M.; Josse, R.G.; Prior, J.C.; Towheed, T.E.; et al. Longitudinal Changes in Calcium and Vitamin D Intakes and Relationship to Bone Mineral Density in a Prospective Population-Based Study: The Canadian Multicentre Osteoporosis Study (CaMos). J. Musculoskelet. Neuronal Interact. 2013, 13, 470.
  51. Neville, C.E.; Robson, P.J.; Murray, L.J.; Strain, J.J.; Twisk, J.; Gallagher, A.M.; McGuinness, M.; Cran, G.W.; Ralston, S.H.; Boreham, C.A.G. The Effect of Nutrient Intake on Bone Mineral Status in Young Adults: The Northern Ireland Young Hearts Project. Calcif. Tissue Int. 2002, 70, 89–98.
  52. Krstic, N.; Bishop, N.; Curtis, B.; Cooper, C.; Harvey, N.; Lilycrop, K.; Murray, R.; Owen, R.; Reilly, G.; Skerry, T.; et al. Early Life Vitamin D Depletion and Mechanical Loading Determine Methylation Changes in the RUNX2, RXRA, and Osterix Promoters in Mice. Genes Nutr. 2022, 17, 7.
  53. Scheller, E.L.; Khoury, B.; Moller, K.L.; Wee, N.K.Y.; Khandaker, S.; Kozloff, K.M.; Abrishami, S.H.; Zamarron, B.F.; Singer, K. Changes in Skeletal Integrity and Marrow Adiposity during High-Fat Diet and after Weight Loss. Front. Endocrinol. 2016, 7, 102.
  54. Tian, L.; Yu, X. Fat, Sugar, and Bone Health: A Complex Relationship. Nutrients 2017, 9, 506.
  55. Weaver, C.M.; Gordon, C.M.; Janz, K.F.; Kalkwarf, H.J.; Lappe, J.M.; Lewis, R.; O’Karma, M.; Wallace, T.C.; Zemel, B.S. The National Osteoporosis Foundation’s Position Statement on Peak Bone Mass Development and Lifestyle Factors: A Systematic Review and Implementation Recommendations. Osteoporos. Int. 2016, 27, 1281–1386.
  56. Karlsson, M.K.; Rosengren, B.E. Exercise and Peak Bone Mass. Curr. Osteoporos. Rep. 2020, 18, 285–290.
  57. Nguyen, V.H. School-Based Exercise Interventions Effectively Increase Bone Mineralization in Children and Adolescents. Osteoporos. Sarcopenia 2018, 4, 39–46.
  58. Larsen, M.N.; Nielsen, C.M.; Helge, E.W.; Madsen, M.; Manniche, V.; Hansen, L.; Hansen, P.R.; Bangsbo, J.; Krustrup, P. Positive Effects on Bone Mineralisation and Muscular Fitness after 10 Months of Intense School-Based Physical Training for Children Aged 8–10 Years: The Fit First Randomised Controlled Trial. Br. J. Sport. Med. 2018, 52, 254–260.
  59. Tang, Y.; Wang, S.; Yi, Q.; Xia, Y.; Geng, B. Sleep Pattern and Bone Mineral Density: A Cross-Sectional Study of National Health and Nutrition Examination Survey (NHANES) 2017–2018. Arch. Osteoporos. 2021, 16, 157.
  60. Ma, M.; Liu, X.; Jia, G.; Liu, Z.; Zhang, K.; He, L.; Geng, B.; Xia, Y. The Association between Depression and Bone Metabolism: A US Nationally Representative Cross-Sectional Study. Arch. Osteoporos. 2022, 17, 113.
  61. Mikkola, T.M.; von Bonsdorff, M.B.; Osmond, C.; Salonen, M.K.; Kajantie, E.; Cooper, C.; Välimäki, M.J.; Eriksson, J.G. Childhood Growth Predicts Higher Bone Mass and Greater Bone Area in Early Old Age: Findings among a Subgroup of Women from the Helsinki Birth Cohort Study. Osteoporos. Int. 2017, 28, 2717–2722.
  62. Baird, J.; Kurshid, M.A.; Kim, M.; Harvey, N.; Dennison, E.; Cooper, C. Does Birthweight Predict Bone Mass in Adulthood? A Systematic Review and Meta-Analysis. Osteoporos. Int. 2011, 22, 1323–1334.
  63. Callréus, M.; McGuigan, F.; Åkesson, K. Birth Weight is More Important for Peak Bone Mineral Content than for Bone Density: The PEAK-25 Study of 1,061 Young Adult Women. Osteoporos. Int. 2013, 24, 1347–1355.
  64. Akhiiarova, K.E.; Gantseva, K.K.; Khusainova, R.I.; Tyurin, A.V. Phenotypic Manifestations of Connective Tissue Dysplasia in Individuals with Joint Hypermobility. Med. Counc. 2022, 156–161.
  65. Yalaev, B.; Tyurin, A.; Prokopenko, I.; Karunas, A.; Khusnutdinova, E.; Khusainova, R. Using a Polygenic Score to Predict the Risk of Developing Primary Osteoporosis. Int. J. Mol. Sci. 2022, 23, 10021.
  66. Yu, W.J.; Zhang, Z.; Fu, W.Z.; He, J.W.; Wang, C.; Zhang, Z.L. Association between LGR4 Polymorphisms and Peak Bone Mineral Density and Body Composition. J. Bone Miner. Metab. 2020, 38, 658–669.
  67. Zheng, Y.; Wang, C.; Zhang, H.; Shao, C.; Gao, L.H.; Li, S.S.; Yu, W.J.; He, J.W.; Fu, W.Z.; Hu, Y.Q.; et al. Polymorphisms in Wnt Signaling Pathway Genes Are Associated with Peak Bone Mineral Density, Lean Mass, and Fat Mass in Chinese Male Nuclear Families. Osteoporos. Int. 2016, 27, 1805–1815.
  68. Zhao, F.; Gao, L.-H.; Li, S.-S.; Wei, Z.-Y.; Fu, W.-Z.; He, J.-W.; Liu, Y.-J.; Hu, Y.-Q.; Dong, J.; Zhang, Z.-L. Association between SNPs and Haplotypes in the METTL21C Gene and Peak Bone Mineral Density and Body Composition in Chinese Male Nuclear Families. J. Bone Miner. Metab. 2017, 35, 437–447.
  69. He, J.W.; Yue, H.; Hu, W.W.; Hu, Y.Q.; Zhang, Z.L. Contribution of the Sclerostin Domain-Containing Protein 1 (SOSTDC1) Gene to Normal Variation of Peak Bone Mineral Density in Chinese Women and Men. J. Bone Miner. Metab. 2011, 29, 571–581.
  70. Chesi, A.; Wagley, Y.; Johnson, M.E.; Manduchi, E.; Su, C.; Lu, S.; Leonard, M.E.; Hodge, K.M.; Pippin, J.A.; Hankenson, K.D.; et al. Genome-Scale Capture C Promoter Interactions Implicate Effector Genes at GWAS Loci for Bone Mineral Density. Nat. Commun. 2019, 10, 1260.
  71. Pippin, J.A.; Chesi, A.; Wagley, Y.; Su, C.; Pahl, M.C.; Hodge, K.M.; Johnson, M.E.; Wells, A.D.; Hankenson, K.D.; Grant, S.F.A. CRISPR-Cas9–Mediated Genome Editing Confirms EPDR1 as an Effector Gene at the BMD GWAS-Implicated ‘STARD3NL’ Locus. JBMR Plus 2021, 5, e10531.
  72. Zheng, H.F.; Tobias, J.H.; Duncan, E.; Evans, D.M.; Eriksson, J.; Paternoster, L.; Yerges-Armstrong, L.M.; Lehtimäki, T.; Bergström, U.; Kähönen, M.; et al. WNT16 Influences Bone Mineral Density, Cortical Bone Thickness, Bone Strength, and Osteoporotic Fracture Risk. PLoS Genet. 2012, 8, e1002745.
  73. Mullin, B.H.; Walsh, J.P.; Zheng, H.F.; Brown, S.J.; Surdulescu, G.L.; Curtis, C.; Breen, G.; Dudbridge, F.; Richards, J.B.; Spector, T.D.; et al. Genome-Wide Association Study Using Family-Based Cohorts Identifies the WLS and CCDC170/ESR1 Loci as Associated with Bone Mineral Density. BMC Genom. 2016, 17, 136.
  74. Luo, F.; Xie, Y.; Chen, H.; Huang, J.; Li, C.; Chen, L.; Yang, J.; Su, N. Fgfr1 Deficiency in Osteocytes Leads to Increased Bone Mass by Enhancing Wnt/β-Catenin Signaling. Bone 2023, 174, 116817.
Subjects: Rheumatology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : , , , ,
View Times: 119
Revisions: 2 times (View History)
Update Date: 30 Nov 2023
Video Production Service